Juliette Ortholand

ORCID: 0000-0003-3197-0424
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Amyotrophic Lateral Sclerosis Research
  • Health Systems, Economic Evaluations, Quality of Life
  • Parkinson's Disease Mechanisms and Treatments
  • Dementia and Cognitive Impairment Research
  • Health, Environment, Cognitive Aging
  • Neurological diseases and metabolism
  • Spatial and Panel Data Analysis
  • Experimental Behavioral Economics Studies
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Neurogenetic and Muscular Disorders Research
  • Inflammatory Myopathies and Dermatomyositis
  • Biomedical Text Mining and Ontologies
  • Auction Theory and Applications
  • Imbalanced Data Classification Techniques
  • Cytokine Signaling Pathways and Interactions
  • Cholinesterase and Neurodegenerative Diseases

Institut du Cerveau
2022-2024

Inserm
2023-2024

Pitié-Salpêtrière Hospital
2024

Assistance Publique – Hôpitaux de Paris
2023-2024

Sorbonne Université
2023-2024

Institut national de recherche en informatique et en automatique
2024

Allen Institute for Brain Science
2022-2024

Centre National de la Recherche Scientifique
2023-2024

Université de Technologie de Compiègne
2020

Heuristics and Diagnostics for Complex Systems
2020

Abstract The anticipation of progression Alzheimer’s disease (AD) is crucial for evaluations secondary prevention measures thought to modify the trajectory. However, it difficult forecast natural AD, notably because several functions decline at different ages and rates in patients. We evaluate here AD Course Map, a statistical model predicting neuropsychological assessments imaging biomarkers patient from current medical radiological data early stages. tested method on more than 96,000...

10.1038/s41467-022-35712-5 article EN cc-by Nature Communications 2023-02-10

Non-terminal events can represent a meaningful change in patient's life. Thus, better understanding and predicting their occurrence bring valuable information to individuals. In context where longitudinal markers could inform these events, joint models with competing risks have been developed. Their precision relies on reference time for which disease onset is often used. Nevertheless, chronic diseases no clear onset, making it difficult define precise time. We propose Joint cause-specific...

10.48550/arxiv.2501.08960 preprint EN arXiv (Cornell University) 2025-01-15

Introduction: Heterogeneity of the progression neurodegenerative diseases is one main challenges faced in developing effective therapies. With increasing number large clinical databases, disease models have led to a better understanding this heterogeneity. Nevertheless, these may no clear onset and biological underlying processes start before first symptoms. Such an ill-defined reference time issue for current joint models, which proven their effectiveness by combining longitudinal survival...

10.48550/arxiv.2401.17249 preprint EN arXiv (Cornell University) 2024-01-30

La sclérose latérale amyotrophique (SLA) est une maladie neurodégénérative rare associée à des manifestations cliniques variées. Nous proposons approche centrée sur l'étude parcours de soins patients atteints la SLA pour décrire temporalité et diversité prises en charge. Après sélection incidents enregistrés dans base MCO l'ATIH, nous avons comparé les dynamiques transition survenue interventions cliniques, intervenant progression maladie, via un modèle multi-états semi-Markovien temps...

10.1016/j.jeph.2024.202317 article FR Deleted Journal 2024-03-01

La Sclérose latérale amyotrophique (SLA) est une maladie neurodégénérative rare, associée à des manifestations cliniques hétérogènes et restreinte prise en charge exclusivement de support symptomatique. L'évaluation bénéfices du délai d'initiation interventions majeures impliquées dans la restent un défi pour les cliniciens d'autant plus exacerbé par l'hétérogénéité délais rapportés parfois variables littérature. Ainsi, nous proposons approche centrée sur l'étude parcours soins hospitaliers...

10.1016/j.jeph.2024.202408 article FR Deleted Journal 2024-05-01

Background and objectives: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive motor neuron degeneration resulting in loss of muscle function. Care management restricted to symptomatic palliative strategies, while clinical manifestations are heterogeneous. However, assessing the timing benefits ALS major interventions remains challenging, with varying nonspecific time-to-events estimates reported literature. Consequently, we proposed retrospective...

10.1159/000542300 article EN Neuroepidemiology 2024-12-23
Coming Soon ...